Get the Stockscreener App
57.78
1.10%
0.63
After Hours:
57.70
-0.08
-0.14%
Boston Scientific Corp stock is traded at $57.78, with a volume of 11.69M.
It is up +1.10% in the last 24 hours and down -10.93% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$57.15
Open:
$57.6
24h Volume:
11.69M
Relative Volume:
0.72
Market Cap:
$85.88B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
24.23
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
+9.68%
1M Performance:
-10.93%
6M Performance:
-40.36%
1Y Performance:
-44.71%
1-Day Range:
$57.39
$58.51
1-Week Range:
$53.45
$58.51
52-Week Range:
$52.52
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corp. stock (US10117L1017): Pipeline momentum and earnings keep medtech investor i - AD HOC NEWS
Boston Scientific (BSX) Invests $1.5B in MiRus for Significant E - GuruFocus
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific’s SWOT analysis: stock navigates strategic expansion - Investing.com
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
Insider Buying: Cheryl Pegus Acquires Shares of Boston Scientifi - GuruFocus
Boston Scientific director Cheryl Pegus buys $99,987 in stock - Investing.com UK
Boston Scientific director Ludwig buys $202,914 in stock By Investing.com - Investing.com Australia
Boston Scientific director Ludwig buys $202,914 in stock - Investing.com
Director Cheryl Pegus buys Boston Scientific (BSX) shares in open-market trade - Stock Titan
Director Edward J. Ludwig buys 3,580 Boston Scientific (BSX) shares in open market - Stock Titan
Boston Scientific (NYSE: BSX) director adds 4,450 company shares - Stock Titan
Boston Scientific Corp (NYSE:BSX) GARP Growth at a Reasonable Price Meets Strong Fundamentals - ChartMill
BSX Stock Price, Quote & Chart | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Boston Scientific’s strategic investment in MiRus includes option to acquire TAVR system - Today's Medical Developments
Mengis Capital Management, Inc.'s Boston Scientific Corp(BSX) Holding History - GuruFocus
Subgroup analysis of the Champion-AF trial shows age not a factor - BioWorld News
Boston Scientific stock (US10117L1017): Q1 sales rise as Wall Street tracks procedure demand - AD HOC NEWS
Boston Scientific Corporation (BSX) Fell Due to Weak Results - Yahoo Finance
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target - Insider Monkey
ODDO BHF ASSET MANAGEMENT SAS's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific Corp. stock (US10117L1017): market eyes next catalysts after recent updates - AD HOC NEWS
OXFORD ASSET MANAGEMENT LLP's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (BSX) Achieves Positive Results in CAD Treatme - GuruFocus
Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results - Benzinga
Boston Scientific reports Seismiq IVL data from Fracture study - BioWorld News
Boston Scientific’s coronary IVL catheter hits primary endpoints in trial - Yahoo Finance
Boston Scientific stock rating reiterated at Buy by TD Cowen - Investing.com
Piper Sandler reiterates Boston Scientific stock rating on device outlook - Investing.com
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy? - Yahoo Finance
Boston Scientific coronary device meets trial endpoints - Investing.com
Boston Scientific posts positive data for coronary IVL catheter - Yahoo Finance
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints - Morningstar
Boston Scientific invests $1.5bn for equity stake in MiRus - Yahoo Finance
Boston Scientific Corp (BSX) Stock Up 6.2% and Still Undervalued -- GF Score: 83/100 - GuruFocus
Boston Scientific stock (US10117L1017): New catalyst watch after recent company developments - AD HOC NEWS
Boston Scientific Pairs US$2b Buyback With MiRus TAVR Growth Bet - Yahoo Finance
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years - Benzinga
Joel Greenblatt's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (BSX) Announces $2 Billion Accelerated Share R - GuruFocus
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement - TradingKey
Boston Scientific invests $1.5B in MiRus heart valve startup - Yahoo Finance
Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal - Benzinga
BSX Reiterated by Needham -- Price Target Maintained at $77.00 - GuruFocus
Boston Scientific Bets on Growth Through Strategic M&A Deals - Yahoo Finance
Boston Scientific (BSX) Invests $1.5B in MiRus for 34% Equity St - GuruFocus
Boston Scientific returns to heart-valve market with $1.5B investment in startup - The Business Journals
Boston Scientific Invests $1.5 Billion in MiRus for Exclusive Option on Innovative Nickel-Free Balloon Expandable TAVR Valve - Minichart
Boston Scientific Announces $2 Billion Accelerated Share Repurchase Agreement to Boost Shareholder Value - Minichart
Truist reiterates Boston Scientific stock rating on MiRus deal - Investing.com
Boston Scientific (BSX) Invests $1.5B in MiRus for Cardiovascula - GuruFocus
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):